SGIP1 has been found as a potential therapeutic target for obesity- and diabetes-related symptoms, since the selective reduction of the expression of SGIP1 consequenced with inhibition of food intake and the decrement of body weight in rat models (70). The gene discussed is SGIP1; the disease is obesity due to melanocortin 4 receptor deficiency.